Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development
Neuro-Oncology Practice · 04.06.2025 · 12 (3) · 448-457
DOI: 10.1093/nop/npae118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 03.12.2024. Verfasst von Toshihiko Iuchi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: KAKENHI.
Abstract (Originalsprache)
Background
Preventing Type I leptomeningeal metastasis (LM) is critical when treating brain metastases (BMs). The aim of this study was to extract risk factors for Type I LM and to clarify the optimal treatment for BMs from the perspective of Type I LM prevention.
Methods
The clinical course of consecutive cases of BMs derived from non-small cell lung cancer (NSCLC) treated at our hospital was retrospectively evaluated. The relationship between clinicopathological factors, including molecular background, and Type I LM development was verified. In addition, the difference in the time to Type I LM because of treatment for BMs was evaluated to clarify the effectiveness of each treatment in preventing Type I LM.
Results
Of 784 patients with BMs, 44 exhibited Type I LM at the onset of BMs. Poor performance status (P < .0001) and mutated epidermal growth factor receptor (EGFR) gene (P = .004) were significant risk factors for Type I LM. Among the 740 patients without LMC at diagnosis, 85 developed Type I LM. Younger age (P = .011) and mutated EGFR (P < .0001) were risk factors for developing LMC after BMs. Osimertinib reduced the incidence of Type I LM (hazard ratio [HR]: 0.48; 95% confidence interval [CI]: 0.24-0.97) in EGFR-mutated cases. Immune checkpoint inhibitors (ICIs) showed a tendency to prolong the time to Type I LM (HR: 0.15; 95% CI: 0.02-1.11) in EGFR-wild-type cases.
Conclusions
Patients with EGFR-mutated NSCLC are prone to developing Type I LM. Osimertinib for EGFR-mutated cases and ICIs are expected to prevent Type I LM after the diagnosis of BMs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurological Surgery, Chiba Cancer Center, Chiba, Japan.
- Division of Respirology, Chiba Cancer Center, Chiba, Japan.
ORCID-Profile: Toshihiko Iuchi
Förderung
- KAKENHI
Zitieren
APA
Iuchi, T., Shingyoji, M., Mizuno, S., Ashinuma, H., Hasegawa, Y., Setoguchi, T., Hosono, J., & Sakaida, T. (2025). Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development. Neuro-Oncology Practice, 12(3), 448-457. https://doi.org/10.1093/nop/npae118
Vancouver
Iuchi T, Shingyoji M, Mizuno S, Ashinuma H, Hasegawa Y, Setoguchi T, et al. Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development. Neuro-Oncology Practice. 2025;12(3):448-457. doi:10.1093/nop/npae118
BibTeX
@article{Iuchi2025,
author = {Iuchi, Toshihiko and Shingyoji, Masato and Mizuno, Satoko and Ashinuma, Hironori and Hasegawa, Yuzo and Setoguchi, Taiki and Hosono, Junji and Sakaida, Tsukasa},
title = {Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development},
journal = {Neuro-Oncology Practice},
year = {2025},
volume = {12},
number = {3},
pages = {448--457},
doi = {10.1093/nop/npae118}
}
EUVIMED